Join
Live feed
·
PRReleasevia Quantisnow
Palvella Therapeutics Inc. logo

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

ByQuantisnow·Wall Street's wire, on your screen.
PVLA· Palvella Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PVLA (Palvella Therapeutics Inc.) and more on Quantisnow.